Becton, Dickinson and Company

BDX · NYSE · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net −$368K – $215K 8 disclosures · 6 bought / 2 sold · last Jul 31, 2026
Thad Cochran R · HOUSE · MS	$15K – $50K $21K – $71K today 1 filing · last Jan 5, 2015
Ro Khanna D · HOUSE · CA	−$625K – $670K −$578K – $610K today 76 filings · last Jun 2, 2026
Richard L. Hanna R · HOUSE · NY	$2K – $30K $4K – $53K today 2 filings · last May 2, 2014
Shelley Moore Capito R · SENATE · WV	−$12K – $44K −$9K – $45K today 4 filings · last Feb 15, 2024
Thomas J. Rooney R · HOUSE · FL	−$12K – $44K −$12K – $52K today 4 filings · last Sep 22, 2017
Thomas H. Kean, Jr. R · HOUSE · NJ	−$12K – $44K −$18K – $41K today 4 filings · last May 21, 2026
Dean Phillips D · HOUSE · MN	$1K – $15K $918 – $14K today 1 filing · last Jan 4, 2019
Marjorie Taylor Greene R · HOUSE · GA	$1K – $15K $824 – $12K today 1 filing · last May 12, 2021
Alan Armstrong R · SENATE · OK	$1K – $15K $1K – $19K today 1 filing · last Mar 27, 2026

Recent transactions

Trades from Feb 19, 2025 – Jul 31, 2026

Politician	Type	Filed after	Amount
Donald Trump R · EXECUTIVE	Buy	53 days Jul 31, 2026 → Sep 22, 2026	≥$100K
Donald Trump R · EXECUTIVE	Buy	67 days Jun 16, 2026 → Aug 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	71 days Jun 12, 2026 → Aug 22, 2026	≥$15K
Alan Armstrong R · SENATE · OK	Buy	116 days Mar 27, 2026 → Jul 21, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	34 days Jun 2, 2026 → Jul 6, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	47 days May 15, 2026 → Jul 1, 2026	≥$1K
Thomas H. Kean, Jr. R · HOUSE · NJ-7	Sell	28 days May 21, 2026 → Jun 18, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	13 days May 27, 2026 → Jun 9, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	25 days May 15, 2026 → Jun 9, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	39 days May 1, 2026 → Jun 9, 2026	≥$1K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

1,473

13F shares

268M

Total invested

$41.7B

Ownership

95.5%

New positions

141

Closed positions

174

Increased positions

690

Reduced positions

554

Put/Call ratio

0.58

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	24.6M	$3.7B	−5.97%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	18M	$2.7B	−2.72%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	8/3/2026	8.7M	$2.5B	−4.95%
STATE STREET CORP	9/22/2026	15M	$2.3B	+8.52%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	15M	$2.3B	−2.24%
FIRST EAGLE INVESTMENT MANAGEMENT, LLC	8/24/2026	13.8M	$2.1B	+15.82%
INVESCO LTD.	8/14/2026	8.9M	$1.3B	−12.54%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	8.1M	$1.2B	+14.55%
FRANKLIN RESOURCES INC	8/13/2026	7M	$1.1B	+30.74%
WELLINGTON MANAGEMENT GROUP LLP	8/14/2026	6.4M	$962.2M	−3.89%
GREENHAVEN ASSOCIATES INC	7/28/2026	5.7M	$859.8M	—
NORGES BANK	8/12/2026	4.2M	$631.0M	—
PRICE T ROWE ASSOCIATES INC /MD/	8/14/2026	3.9M	$591.4M	−11.57%
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.	8/14/2026	3.7M	$563.4M	−61.56%
AMERICAN CENTURY COMPANIES INC	8/12/2026	3.7M	$556.4M	+7.95%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	3.4M	$515.3M	+2.23%
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	3.4M	$515.3M	—
MORGAN STANLEY	8/13/2026	3.3M	$502.4M	−17.44%
CLEARBRIDGE INVESTMENTS, LLC	8/13/2026	3.2M	$489.2M	−21.91%
BANK OF AMERICA CORP /DE/	8/14/2026	3.1M	$475.0M	+17.63%
JPMORGAN CHASE & CO	8/12/2026	2.8M	$440.1M	−20.58%
NORTHERN TRUST CORP	8/13/2026	2.6M	$397.3M	+4.94%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	8/13/2026	2.5M	$385.0M	+153.81%
HARRIS ASSOCIATES L P	8/14/2026	2.4M	$355.8M	+5.80%
DIMENSIONAL FUND ADVISORS LP	8/11/2026	2.1M	$324.1M	−5.76%

Insider transactions

Insider	Type	Transacted	Price	Date
Feld Michael	S-SALE	76	$183.70	Sep 28
Roque Vitor	F-INKIND	190	—	Sep 2
Feld Michael	S-SALE	165	$188.49	Aug 26
Feld Michael	F-INKIND	1K	—	Aug 20
Polen Thomas E Jr	S-SALE	4.2K	$185.00	Aug 13
Polen Thomas E Jr	M-EXEMPT	43.3K	$167.25	Aug 13
Polen Thomas E Jr	M-EXEMPT	43.3K	$167.25	Aug 13
Polen Thomas E Jr	D-RETURN	39.1K	$185.00	Aug 13
Goette Roland	S-SALE	2.4K	$180.84	Aug 11
Huffines Robert Luther	A-AWARD	189	—	Aug 6

Analyst consensus

Hold34 analysts

Bearish · 1 · Hold · 17 · Bullish · 16

Earnings history

	EPS	Estimate
Q4 2024	$3.81	$3.77	Beat
Q1 2025	$3.43	$3.00	Beat
Q2 2025	$3.35	$3.28	Beat
Q3 2025	$3.68	$3.40	Beat
Q4 2025	$3.96	$3.92	Beat
Q1 2026	$2.91	$2.21	Beat
Q2 2026	$2.90	$2.78	Beat
Q3 2026	$3.23	$3.14	Beat

Peers

Company overview

IPO dateFeb 21, 1973

CEOThomas E. Polen Jr.

Employees72,000

SectorHealthcare

IndustryMedical - Instruments & Supplies

CountryUS

ExchangeNew York Stock Exchange

Websitewww.bd.com

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.